索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]陈飏,李赵龙,李海清,等.缺血性二尖瓣反流的治疗[J].国际心血管病杂志,2022,02:75-79,82.
点击复制

缺血性二尖瓣反流的治疗(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年02期
页码:
75-79,82
栏目:
综述
出版日期:
2022-06-01

文章信息/Info

Title:
-
作者:
陈飏; 李赵龙; 李海清; 赵强
缺血性二尖瓣反流（IMR）是冠状动脉粥样硬化性心脏病的常见并发症。左 室重构是IMR 的主要发生机制。心肌梗死后发生IMR 是预后不良的危险因素。对于重度 IMR 患者，在冠状动脉旁路移植术（CABG）同期处理二尖瓣已形成共识，但对于中度 IMR 患者，CABG 同期是否行二尖瓣成形术尚存争议。该文介绍IMR 的发生机制、反流程度的 评估及治疗措施。
Author(s):
-
关键词:
-
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.02.004
文献标识码:
-
摘要:
缺血性二尖瓣反流；冠状动脉粥样硬化性心脏病；冠状动脉旁路移植术；二尖 瓣修复；二尖瓣置换
Abstract:
-

参考文献/References

[1] Petris AO, Iliescu D, Alexandrescu DM, et al. Ischemic mitral regurgitation in patients with acute myocardial infarction[J]. Rev Med Chir Soc Med Nat Iasi, 2014, 118(3):618-623.
[2] Varma PK, Krishna N, Jose RL, et al. Ischemic mitral regurgitation[J]. Ann Card Anaesth, 2017, 20(4):432-439.
[3] Báez-Ferrer N, Izquierdo-Gómez MM, Marí-López B, et al. Clinical manifestations, diagnosis, and treatment of ischemic mitral regurgitation: a review[J]. J Thorac Dis, 2018, 10(12):6969-6986.
[4] Piérard LA, Carabello B. Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment[J]. Eur Heart J, 2010, 31(24):2996-3005.
[5] Dal-Bianco JP, Levine RA. Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography[J]. Cardiol Clin, 2013, 31(2):151-164.
[6] Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation[J]. Circulation, 2005, 111(3):295-301.
[7] Bach DS, Deeb GM, Bolling SF. Accuracy of intraoperative transesophageal echocardiography for estimating the severity of functional mitral regurgitation[J]. Am J Cardiol, 1995, 76(7):508-512.
[8] American Association for Thoracic Surgery Ischemic Mitral Regurgitation Consensus Guidelines Writing Committee, Kron IL, Acker MA, et al. 2015 The American Association for Thoracic Surgery Consensus Guidelines: ischemic mitral valve regurgitation[J]. J Thorac Cardiovasc Surg, 2016, 151(4):940- 956.
[9] Lancellotti P, Troisfontaines P, Toussaint AC, et al. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction[J]. Circulation, 2003, 108(14):1713-1717.
[10] Ko SM, Song MG, Hwang HK. Evaluation of the aortic and mitral valves with cardiac computed tomography and cardiac magnetic resonance imaging[J]. Int J Cardiovasc Imaging, 2012:109-127.
[11] Lam CSP, Li YH, Bayes-Genis A, et al. The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure[J]. J Chin Med Assoc, 2019, 82(6):447-451.
[12] Capomolla S, Febo O, Gnemmi M, et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol[J]. Am Heart J, 2000, 139(4):596-608.
[13] Comin-Colet J, Sánchez-Corral MA, Manito N, et al. Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction[J]. Transplant Proc, 2002, 34(1):177-178.
[14] McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J]. Eur J Heart Fail, 2013, 15(9):1062-1073.
[15] Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation[J]. Circulation, 2019, 139(11):1354-1365.
[16] Nappi F, Avtaar SS, Padala M, et al. The choice of treatment in ischemic mitral regurgitation with reduced left ventricular function[J]. Ann Thorac Surg, 2019, 108(6):1901-1912.
[17] Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation, 2013, 128(16):e240-e327.
[18] Ojo A, Tariq S, Harikrishnan P, et al. Cardiac resynchronization therapy for heart failure[J]. Interv Cardiol Clin, 2017, 6(3):417-426.
[19] Van Bommel RJ, Marsan N, Delgado V, et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk[J]. Circulation, 2011, 124(8):912-919.
[20] Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/ HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the ACC/ AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 2008, 51(21):e1-e62.
[21] Calafiore AM, Iacò AL, Gallina S, et al. Surgical treatment of functional mitral regurgitation[J]. Int J Cardiol, 2013, 166(3):559-571.
[22] Bouchard D, Jensen H, Carrier M, et al. Effect of systematic downsizing rigid ring annuloplasty in patients with moderate ischemic mitral regurgitation[J]. J Thorac Cardiovasc Surg, 2014, 147(5):1471-1477.
[23] Maltais S, Schaff HV, Daly RC, et al. Mitral regurgitation surgery in patients with ischemic cardiomyopathy and ischemic mitral regurgitation: factors that influence survival[J]. J Thorac Cardiovasc Surg, 2011, 142(5):995-1001.
[24] Acker MA, Parides MK, Perrault LP, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation[J]. N Engl J Med, 2014, 370(1):23-32.
[25] Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation[J]. N Engl J Med, 2016, 374(4):344-353.
[26] Smith PK, Hung JW, Michler RE. Surgical treatment of moderate ischemic mitral regurgitation[J]. N Engl J Med, 2015, 372(18):1773-1774.
[27] Michler RE, Smith PK, Parides MK, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation[J]. N Engl J Med, 2016, 374(20):1932-1941.
[28] Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg, 2012, 42(4):S1-S44.
[29] Christenson JT, Simonet F, Bloch A, et al. Should a mild to moderate ischemic mitral valve regurgitation in patients with poor left ventricular function be repaired or not?[J]. J Heart Valve Dis, 1995, 4(5):484-488.
[30] Altarabsheh SE, Deo SV, Rababa'h A, et al. Chronic ischemic mitral valve regurgitation and surgical perspectives[J]. World J Cardiol, 2018, 10(10):141-144.
[31] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation, 2013, 128(16):1810-1852.
[32] Kopjar T, Gasparovic H, Mestres CA, et al. Meta-analysis of concomitant mitral valve repair and coronary artery bypass surgery versus isolated coronary artery bypass surgery in patients with moderate ischaemic mitral regurgitation[J]. Eur J Cardiothorac Surg, 2016, 50(2):212-222.
[33] Chan KM, Punjabi PP, Flather M, et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial[J]. Circulation, 2012, 126(21):2502-2510.
[34] Sun X, Jiang Y, Huang G, et al. Three-dimensional mitral valve structure in predicting moderate ischemic mitral regurgitation improvement after coronary artery bypass grafting[J]. J Thorac Cardiovasc Surg, 2019, 157(5):1795-1803.
[35] AATS Ischemic Mitral Regurgitation Consensus Guidelines Writing Committee, Kron IL, LaPar DJ, et al. 2016 update to the American Association for Thoracic Surgery (AATS) consensus guidelines: ischemic mitral valve regurgitation[J]. J Thorac Cardiovasc Surg, 2017, 153(5):e97-e114.
[36] Passaroni AC, Felicio ML, Campos N, et al. Hemolysis and inflammatory response to extracorporeal circulation during on-pump CABG: comparison between roller and centrifugal pump systems[J]. Braz J Cardiovasc Surg, 2018, 33(1):64-71.
[37] Lewis C, Parulkar SD, Bebawy J, et al. Cerebral neuromonitoring during cardiac surgery: a critical appraisal with an emphasis on near-infrared spectroscopy[J]. J Cardiothorac Vasc Anesth, 2018, 32(5):2313-2322.
[38] Boehne M, Sasse M, Karch A, et al. Systemic inflammatory response syndrome after pediatric congenital heart surgery: incidence, risk factors, and clinical outcome[J]. J Card Surg, 2017, 32(2):116-125.
[39] Raja SG, Husain M, Salhiyyah K, et al. Concomitant offpump coronary artery bypass grafting results in improved in-hospital outcomes for patients with ischemic mitral regurgitation undergoing surgery[J]. Heart Surg Forum, 2013, 16(1):E15-E20.
[40] Kron IL, Hung J, Overbey JR, et al. Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation[J]. J Thorac Cardiovasc Surg, 2015, 149(3):752-761.
[41] Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure[J]. N Engl J Med, 2018, 379(24):2307-2318.
[42] Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation[J]. N Engl J Med, 2018, 379(24):2297-2306.

备注/Memo

备注/Memo:
作者单位：200025 上海交通大学医学院附属瑞金医院心脏外科
通信作者：赵强, E-mail: zq11607@rjh.com.cn
更新日期/Last Update: 2022-06-01